Compare Abbott Laboratories (ABT) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Global X Lithium & Battery Tech ETF — how do they compare? Abbott Laboratories trades at $95.2 (market cap $166.94B), while Global X Lithium & Battery Tech ETF trades at $72.05. The key difference: Abbott Laboratories pays a 2.63% dividend while Global X Lithium & Battery Tech ETF pays none, and Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Abbott Laboratories nearer its low. Which is the better fit depends on your goals.
| ABT | LIT | |
|---|---|---|
Market Cap | $166.94B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $136.62 | $91.62 |
52-Week Low | $82.57 | $39.41 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.18, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. The stock shows solid fundamentals with a P/E of 26.85, net income margin of 13.91%, and consistent dividend payments. Recent news highlights CE Mark approval for Libre Duo systems and positive diagnostic portfolio developments, supporting growth prospects in healthcare markets.
Outlook remains positive with a consensus price target of $122.55 implying 29% upside, though risks include competitive pressures and macroeconomic volatility. Earnings beat in Q1 2026 offsets prior misses, while cash flow stability and declining debt-to-asset ratio (15.02% in 2025) reinforce financial health. Institutional sentiment is strongly bullish with 75.6% buy ratings.
LIT (Global X Lithium & Battery Tech ETF) trades at $76.17, down 0.47% with a bearish technical outlook. The ETF faces selling pressure from moving averages but maintains neutral oscillator readings. Recent news highlights strong momentum driven by energy storage, semiconductors, and EV demand, with the fund returning 125% from last year's lows according to 24/7 Wall Street on June 7, 2026. Key financial ratios remain undisclosed in current data.
Outlook remains mixed with technical weakness offset by strong sector catalysts. Investment opportunity lies in exposure to lithium and battery technology growth, particularly from EV and AI demand. Risks include reliance on Chinese supply chains, regulatory changes, and commodity price volatility. The upcoming dividend of $0.32 per share scheduled for July 2026 provides income potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
